New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 2, 2009, Pages 598-609

  Storme, Thomas ^b   Deroussent, Alain ^a   Mercier, Lionel ^a   Prost, Elise ^b   Re, Micheline ^a   Munier, Fabienne ^a   Martens, Thierry ^b   Bourget, Philippe ^a   Vassal, Gilles ^a   Royer, Jacques ^b   Paci, Angelo ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DIMETHYLIFOSFAMIDE; IFOSFAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG CYTOTOXICITY; DRUG TRANSFORMATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOTRANSFORMATION; CELLS, CULTURED; HUMANS; IFOSFAMIDE; KINETICS; MALE; NEPHROTIC SYNDROME; NEUROTOXICITY SYNDROMES; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 59649125837     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.144170     Document Type: Article

References (30)

1. Abernathy CO, Philpot RM, Guthrie FE, and Hodgson E (1971) Inductive effects of 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane(DDT), phenobarbital, and benzpyrene on microsomal cytochrome B450, ethyl isocyanide spectra, and metabolism in vivo of zoxazolamine and hexobarbital in the mouse. Biochem Pharmacol 20:2395-2400.
2. Ajithkumar T, Parkinson C, Shamshad F, and Murray P (2007) Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 19:108-114.
3. Aleksa K, Woodland C, and Koren G (2001) Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies. Pediatr Nephrol 16:1153-1158.
4. Baldwin A, Huang Z, Jounaidi Y, and Waxman DJ (2003) Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Arch Biochem Biophys 409:197-206.
5. Boal JH, Williamson M, Boyd VL, Ludeman SM, and Egan W (1989) 31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: comparisons with phosphoramide mustard. J Med Chem 32:1768-1773.
6. Boddy AV and Yule SM (2000) Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 38:291-304.
7. Brüggemann SK, Radike K, Braasch K, Hinrichs J, Kisro J, Hagenah W, Peters SO, and Wagner T (2006) Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite. Cancer Chemother Pharmacol 57:349-356.
8. Chang TK, Weber GF, Crespi CL, and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637.
9. Chatton JY, Idle JR, Vågbø CB, and Magistretti PJ (2001) Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons. J Pharmacol Exp Ther 299:1161-1168.
10. Clarke L and Waxman DJ (1989) Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 49:2344-2350.
11. Dufour C, Grill J, Sabouraud P, Behar C, Munzer M, Motte J, Oberlin O, Paci A, and Hartmann O (2006) [Ifosfamide induced encephalopathy: 15 observations]. Arch Pediatr 13:140-145.
12. Kerbusch T, de Kraker J, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, Schellens JH, and Beijnen JH (2001) Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 40:41-62.
13. Küpfer A, Aeschlimann C, and Cerny T (1996) Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 50:249-252.
14. Kuzmic P (1996) Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. Anal Biochem 237:260-273.
15. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, and Genin J (1995) High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13:1600-1608.
16. Lee BS, Lee JH, Kang HG, Hahn H, Lee JH, Shin HY, Ha IS, Cheong HI, Ahn HS, and Choi Y (2001) Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr Nephrol 16:796-799.
17. Liu Z, Chan KK, and Wang JJ (2005) Tandem mass spectrometric analysis of cyclophosphamide, ifosfamide and their metabolites. Rapid Commun Mass Spectrom 19:2581-2590.
18. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
19. Paci A, Guillaume D, and Husson H-P (2001) Synthesis of side-chain-substituted ifosfamide analogues. J Heterocycl Chem 38:1131-1134.
20. Patzer L, Hernando N, Ziegler U, Beck-Schimmer B, Biber J, and Murer H (2006) Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells. Kidney Int 70:1725-1734.
21. Ryan DE and Levin W (1990) Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 45:153-239.
22. Sargent EV, Kirk GD, and Hite M (1986) Hazard evaluation of monochloroacetone. Am Ind Hyg Assoc J 47:375-378.
23. Scripture CD, Sparreboom A, and Figg WD (2005) Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 6:780-789.
24. Shaka AJ, Keeler J, Frenkiel T, and Freeman R (1983) An improved sequence for broadband decoupling: WALTZ-16. J Magn Reson 52:335-338.
25. Springer JB, Chang YH, Koo KI, Colvin OM, Colvin ME, Dolan ME, Delaney SM, Flowers JL, and Ludeman SM (2004) 1,3- vs 1,5-Intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards. Chem Res Toxicol 17:1217-1226.
26. Springer JB, Colvin ME, Colvin OM, and Ludeman SM (1998) Isophosphoramide mustard and its mechanism of bisalkylation. J Org Chem 63:7218-7222.
27. Storme T, Mercier L, Deroussent A, Re M, Martens T, Royer J, Bourget P, Vassal G, and Paci A (2005) Liquid chromatography-mass spectrometry assay for quantitation of ifosfamide and its N-deschloroethylated metabolites in rat microsomal medium. J Chromatogr B Analyt Technol Biomed Life Sci 820:251-259.
28. Visarius TM, Stucki JW, and Lauterburg BH (1999) Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J Pharmacol Exp Ther 289:820-824.
29. Waxman DJ, Morrissey JJ, Naik S, and Jauregui HO (1990) Phenobarbital induction of cytochromes P-450. High-level long-term responsiveness of primary rat hepatocyte cultures to drug induction, and glucocorticoid dependence of the phenobarbital response. Biochem J 271:113-119.
30. Yu L and Waxman DJ (1996) Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab Dispos 24:1254-1262.